July 3, 2019 08:19 AM EDT
R&D

Boston Bio­med­ical's lead drug fiz­zles in dif­fi­cult-to-treat pan­cre­at­ic can­cer

Natalie Grover

Reporter

Months af­ter a com­bi­na­tion of Cel­gene’s Abrax­ane and the chemother­a­py gem­c­itabine stum­bled in a piv­otal study in­volv­ing pan­cre­at­ic can­cer pa­tients who had un­der­gone sur­gi­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times